201 related articles for article (PubMed ID: 19666658)
1. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.
Fan S; Ross C; Mitra S; Kalra P; Heaton J; Hunter J; Plone M; Pritchard N
Nephrol Dial Transplant; 2009 Dec; 24(12):3794-9. PubMed ID: 19666658
[TBL] [Abstract][Full Text] [Related]
2. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.
Delmez J; Block G; Robertson J; Chasan-Taber S; Blair A; Dillon M; Bleyer AJ
Clin Nephrol; 2007 Dec; 68(6):386-91. PubMed ID: 18184521
[TBL] [Abstract][Full Text] [Related]
4. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
Ketteler M; Rix M; Fan S; Pritchard N; Oestergaard O; Chasan-Taber S; Heaton J; Duggal A; Kalra PA
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1125-30. PubMed ID: 18450923
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
Koiwa F; Yokoyama K; Fukagawa M; Terao A; Akizawa T
Nephrology (Carlton); 2017 Apr; 22(4):293-300. PubMed ID: 27496336
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure.
Spaia S
Hippokratia; 2011 Jan; 15(Suppl 1):22-6. PubMed ID: 21897754
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.
Perry CM; Plosker GL
Drugs; 2014 May; 74(7):771-92. PubMed ID: 24811546
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability.
de Francisco AL; Leidig M; Covic AC; Ketteler M; Benedyk-Lorens E; Mircescu GM; Scholz C; Ponce P; Passlick-Deetjen J
Nephrol Dial Transplant; 2010 Nov; 25(11):3707-17. PubMed ID: 20530499
[TBL] [Abstract][Full Text] [Related]
10. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
[TBL] [Abstract][Full Text] [Related]
11. Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.
Katopodis KP; Andrikos EK; Gouva CD; Bairaktari ET; Nikolopoulos PM; Takouli LK; Tzallas CS; Elisaf MS; Pappas MV; Siamopoulos KC
Perit Dial Int; 2006; 26(3):320-7. PubMed ID: 16722024
[TBL] [Abstract][Full Text] [Related]
12. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
13. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
[TBL] [Abstract][Full Text] [Related]
14. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
17. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
